Global Cholera Vaccines Market to Witness Strong Growth due to Favorable Government Initiatives: Revenue Opportunities by Key Players Merck & Co., GlaxoSmithKline, Sanofi and Johnson & Johnson

The Global Cholera Vaccines Market The global Cholera Vaccines market is expected to grow at the growth rate of 10.3% to reach USD 1,367.8 million by 2025.
This comprehensive study reveals the market estimate numbers for different market segments. Along with that, the study covers qualitative insights, strategic bench-marking and thorough competitive landscaping in the report spreading over 90 pages.

As per the World Health Organization (WHO), approximately 172 454 cholera cases were reported from a total of 42 countries in 2015 and this number is projected to increase during the coming years. Similarly, the Health for Life Foundation stated that more than 4 million cholera cases are registered every year and it causes around 30,000 to 142,000 deaths yearly across the globe. Thereby, the rising number of people affected with cholera is one of the potential driver for the market growth. Furthermore, the growth of this market is supported by increasing research and development activities, a growing number of companies investing in this industry coupled with strong clinical pipelines.

For instance, PaxVax, Inc. has a pediatric cholera vaccine in phase IV clinical study that is expected to approve shortly by the U.S. FDA. Further, in June 2016, the company received regulatory approval for Vaxchora, PaxVax, Inc.’s single-dose oral cholera vaccine. This product was the only available vaccine indicated for the protection against cholera in the U.S. Such approvals would, in turn, augment the market growth significantly. However, high treatment cost will pull back the market growth to some extent. For instance, as per the various research studies, cost of protection against conditions such as cholera is more than USD 7 per fully immunized person. Of these, 90% of the cost is for the vaccination.

To request free sample copy:
www.analystviewmarketinsights.com/request_sample/av122/

Key Takeaways:
- Based on different products, Dukoral and Shanchol accounted for the majority share of the global revenue. In 2017, over 80% revenue share was captured by these two products collectively.
- Dukoral is a monovalent inactivated vaccine, composed of Killed whole-cells of V. cholerae O1 and recombinant B-subunit of cholera toxin. This vaccine is manufactured by SBL Vaccin AB, Sweden and Crucell, Leiden, The Netherlands
- Dukoral was the first oral cholera vaccine to get approval in the European Union (EU) during the year 2004
- Whereas, Shanchol is a bivalent inactivated vaccine, composed of Killed whole cells of V. cholerae O1 and V. cholerae O139. This vaccine is developed by Shantha Biotechnics (India) and Sanofi
- Regionally, the demand for cholera vaccine is anticipated to increase in regions such as Africa, Asia and some part of America. According to the World Health Organization data (2014), there were around 55%, 30% and 15% increase in cholera cases in regions such as Africa, Asia, and America respectively.
- Companies namely Pfizer, Inc., Merck & Co., GlaxoSmithKline, Sanofi, and Novartis are actively operating in this industry.
Browse full report with in-depth ToC on “Cholera Vaccines Market, By Products (Dukoral, Shanchol, and Vaxchora), And Geography (North America, Europe, Asia Pacific, And Rest Of The World) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025” at
www.analystviewmarketinsights.com/report-highlight-cholera-vaccines-market-122/

The scope of this report covers the market by its major segments, as follows:
Market, by product: Dukoral, Shanchol and Vaxchora;
Market, by Region: North America, Europe, Asia Pacific, Latin America, Middle East and Africa and Rest of the World; Market, by Country: U.S., Canada, Germany, France, India, and China

Key players profiled in this report with special attention on competitive landscape includes, (can be further customized to include additional 10 profiles of companies):
Merck & Co.
GlaxoSmithKline
Sanofi
Johnson & Johnson
Pfizer, Inc.

Key benefits of the report:
- The report presents a macro and micro-level outlook regarding the industry. Thus, it becomes easy for our clients to perceive the business landscape and take a glimpse of their own standing in it.
- A thorough analysis of relevant statistical data to estimate the market paradigms
- Exceptional understanding of the region and country-specific markets. The report will answer some of the toughest questions regarding the market shares, sizes, forecasts segmentations, and growth specific to the countries.
- Well-designed strategic framework analyzes the market movements including regional expansion, mergers & acquisitions, and new product developments

Find out more by getting in touch: https://www.analystviewmarketinsights.com/get-in-touch/

About Us
AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends for various industries such as Healthcare, Bulk Chemicals, Semiconductors, Electronics, and Foods and Beverages.

Contact Us
Mr. Jose (Press & Marketing Manager)
Corporate Sales, USA
AnalystView Market Insights
Email: sales@analystviewmarketinsights.com
Tel: +91-757-498-5725 (Asia-Pacific Business Centre)
Web: www.analystviewmarketinsights.com

This release was published on openPR.